Alkem stock steadies as Mandva FDA inspection ends without Form 483

Alkem Laboratories is in focus after a US FDA inspection of its Mandva active pharmaceutical ingredient facility ended on October 30, 2026, without Form 483 observations. StockFin.ai lists the inspection outcome among the company's latest filings and frames it as part of a broader period of regulatory and governance attention.

Regulatory outcome supports continuity

The Mandva inspection covered October 26 to 30. The absence of Form 483 observations removes an immediate adverse finding from that inspection, although investors still have to monitor future regulatory actions and the company's execution across its manufacturing network.

Governance remains a watchpoint

Alkem's Audit Committee approved a forensic audit on October 21 into alleged fund misappropriation involving a former employee and procurement irregularities. The company also appointed Laxmikant Tiwari and Nilesh Vartak to senior management positions effective October 12, while CFO Nitin Agrawal's resignation took effect on September 30.

Business and competitive position

Alkem researches, manufactures and commercializes branded and unbranded generic medicines, active pharmaceutical ingredients, biosimilars and nutraceuticals for Indian and international markets. Its main operational base is in Mumbai, India, as shown on the company's corporate contact page. In pharmaceuticals, Alkem is smaller by market capitalization than Cipla and Dr. Reddy's and also competes with Lupin, while maintaining a broad generics and API portfolio.

The BSE Sensex provides the relevant Indian market context for investors: current market coverage.

More news and analyses on Alkem stock.